How to Get Ozempic for Under $100 a Month

Getting Ozempic for under $100 a month is possible for many patients in 2026, but it depends heavily on your insurance status, income, and willingness to navigate manufacturer programs. The most reliable routes are Novo Nordisk's savings card (for insured patients), the NovoCare Patient Assistance Program (for uninsured, low-income patients), and — with caution — compounding pharmacies while semaglutide shortage listings remain active.

What Does Ozempic Actually Cost Without Help?

The list price for Ozempic sits at approximately $968–$1,030 per month (for the 0.5 mg, 1 mg, or 2 mg dose pens) as of early 2026, according to Novo Nordisk wholesale pricing data. Very few patients pay this amount out of pocket. With commercial insurance, the average copay falls between $25 and $150 per month depending on your formulary tier. Without any assistance, Ozempic remains one of the most expensive recurring prescriptions in the United States.

Which Savings Programs Can Get You to Under $100?

1. Novo Nordisk Ozempic Savings Card (Insured Patients)

If you have commercial or private insurance (not Medicare or Medicaid), Novo Nordisk's savings card can reduce your monthly copay to as low as $25 per month. Eligibility requirements as of 2026:

• Must have a valid commercial insurance plan that covers Ozempic
• Cannot be enrolled in any federal or state government insurance program
• Prescription must be for an FDA-approved indication (type 2 diabetes for Ozempic)

Enrollment is done online at the NovoCare website or through your pharmacy. The savings card covers the gap between your copay and up to a capped annual benefit — confirm the current cap when you enroll, as Novo Nordisk adjusts it periodically.

2. NovoCare Patient Assistance Program (Uninsured or Underinsured)

For patients without insurance or whose insurance does not cover Ozempic, the NovoCare PAP provides free medication to qualifying individuals. Income thresholds are updated annually; in 2025–2026, eligibility generally extends to individuals earning up to 400% of the federal poverty level (roughly $60,240 for a single person in 2026). Applications require proof of income and a prescriber signature.

3. Medicare Patients: Inflation Reduction Act Changes

As of January 2026, the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D is fully in effect. For Medicare patients whose plan covers Ozempic (typically for type 2 diabetes), this cap significantly limits maximum yearly spending. Monthly costs vary by plan, but many Medicare beneficiaries are now paying $50–$150/month after reaching their deductible. Ozempic is not yet broadly covered under Medicare for weight loss alone; coverage requires a type 2 diabetes diagnosis.

4. GoodRx and Discount Cards

GoodRx and similar discount programs can reduce Ozempic's cash price to roughly $850–$920/month at major pharmacies — a meaningful discount from list price, but still well above $100. These programs are best used as a bridge while awaiting PAP approval, not as a long-term under-$100 solution.

Is Compounded Semaglutide Still an Option in 2026?

This is one of the most rapidly changing areas in GLP-1 access. In 2024, FDA placed semaglutide on its drug shortage list, which allowed 503A and 503B compounding pharmacies to legally produce compounded semaglutide. Compounded versions were being offered by many telehealth platforms for $150–$350/month — still above $100 for most, but significantly below brand-name pricing.

In late 2024 and into 2025, the FDA began signaling removal of semaglutide from the shortage list, which would effectively ban most compounding. As of early 2026, the legal landscape remains contested, with ongoing litigation between compounding pharmacies and the FDA. Check current FDA shortage list status before pursuing compounded semaglutide, as access may have changed after this article's publication.

Week-by-Week Cost Timeline: What to Expect When Starting

What If Insurance Denies Ozempic Coverage?

Insurance denial is common, especially when Ozempic is prescribed off-label for weight loss rather than type 2 diabetes. Steps to take:

1. Request a prior authorization (PA): Your prescriber submits clinical documentation showing medical necessity. Approval rates improve significantly when A1C levels, comorbidities, and failed prior treatments are documented.
2. File a formal appeal: Insurers are required by law to provide an appeals process. Your prescriber's office can submit a peer-to-peer review with the insurance medical director.
3. Request an exception for formulary coverage: If Ozempic is not on your plan's formulary, ask for a formulary exception citing lack of therapeutic alternatives.
4. Contact your state insurance commissioner: If you believe the denial is improper, your state's insurance commissioner office can intervene.

Frequently Asked Questions